Ngokwemiphumela yesigaba sesibili socwaningo, inhlanganisela yezidakamizwa ezijwayelekile zokunakekelwa ngamakhemikhali i-azacitidine kanye ne-immune checkpoint inhibitor. nivolumab ( i-nivolumab ) ibonise ukuthi izinga lokuphendula kanye nokuphindaphinda kweziguli ezine-leukemia ye-myeloid acute noma ephikisayo ( I-AML ) Izinga lokusinda lilonke liyakhuthaza.
Ucwaningo lulandele iziguli ezingama-70. Ngemuva kwesilinganiso semigqa emi-2 yokwelashwa, i-AML ebuyile ibike inani lokuphendula eliphelele lama-33% kanye nezinga lokuphendula eliphelele lama-22%. Inhlanganisela yezidakamizwa isebenza kakhulu ezigulini ezingakaze zithole ama-hypomethylation agents (HMA) phambilini njenge-azacitidine noma i-decitabine, kanti isilinganiso esiphelele salezi ziguli singama-52%.
Abaphenyi bathi amasampula omnkantsha aqoqwe ngaphambi kokwelashwa akhombisa ukuthi imvamisa yokubikezelwa kwamathambo ama-CD3 nama-CD8 amaseli ngaphambi kokwelashwa kuphakeme. Ngokuyinhloko, i-CD3 ibonakala inezinga eliphezulu lokuzwela nokucaciswa kokubikezela impendulo, ekhombisa ukuthi ingasetshenziswa njenge-biomarker ethembekile yokukhetha iziguli zalolu hlobo lwenhlanganisela. "
Ukwelashwa kufaka phakathi umjovo we-azacitidine nomjovo ongaphansi kwesikhumba we-nivolumab. Yize iziguli eziningi zelashwe ngempumelelo, iziguli eziyi-11% zisenemiphumela emibi noma engabeka impilo engcupheni. Ukusinda okuphelele kwazo zonke iziguli kwakuyizinyanga eziyi-6.3. Izinga lokusinda kweziguli ezaqala ukubuyela emuva kwakuyizinyanga eziyi-10.6, okwakuphindwe kabili inani lokusinda elibonwa nge-azacitidine kuphela ezigulini ezifanayo ku-MD Anderson.
Umcwaningi uDaver uthe ucwaningo lwesigaba III olufanele oluhleliwe luyaqhubeka, futhi sikholelwa ukuthi ukuqaliswa kwama-biomarkers emitholampilo kanye nama-immune ekukhetheni iziguli kungahle kuholele ekuthuthukisweni okuqhubekayo kulezi zinhlobo zokwelashwa ku-AML.
https://medicalxpress.com/news/2018-11-combination-chemotherapy-immunotherapy-effective-phase.html
